A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough

This randomized, double-blind crossover study examined the effects of 2 weeks of treatment with lesogaberan versus placebo in 22 patients with refractory chronic cough. The primary endpoint was the effect of treatment on objective 24-hour cough frequency, as measured using the Vitalograph VitaloJAK. Secondary endpoints included efficacy in symptom association probability-positive versus ‑negative patients (as measured by cough frequency over 24 hours), change in capsaicin-evoked cough response, and patient-reported outcomes related to cough severity and reflux symptoms.